Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
1.580
0.00 (0.00%)
Nov 22, 2024, 4:00 PM EST - Market closed
Cellectar Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 34.26 | 9.56 | 19.87 | 35.7 | 57.17 | 10.61 | Upgrade
|
| Cash & Short-Term Investments | 34.26 | 9.56 | 19.87 | 35.7 | 57.17 | 10.61 | Upgrade
|
| Cash Growth | 80.46% | -51.85% | -44.36% | -37.54% | 438.55% | -19.92% | Upgrade
|
| Prepaid Expenses | 1.64 | 0.89 | 0.66 | 0.87 | 0.77 | 0.77 | Upgrade
|
| Total Current Assets | 35.9 | 10.45 | 20.53 | 36.57 | 57.94 | 11.39 | Upgrade
|
| Property, Plant & Equipment | 1.36 | 1.59 | 0.98 | 0.55 | 0.64 | 0.78 | Upgrade
|
| Other Long-Term Assets | 0.03 | 0.03 | 0.08 | 0.08 | 0.08 | 0.08 | Upgrade
|
| Total Assets | 37.29 | 12.08 | 21.59 | 37.2 | 58.66 | 12.25 | Upgrade
|
| Accounts Payable | 8.3 | 9.18 | 2.56 | 1.41 | 1.43 | 1.28 | Upgrade
|
| Accrued Expenses | - | - | 2.92 | 2.44 | 2.01 | 1.39 | Upgrade
|
| Current Portion of Leases | 0.08 | 0.06 | 0.05 | 0.14 | 0.12 | 0.11 | Upgrade
|
| Other Current Liabilities | 11.93 | 16.12 | 5.97 | - | - | - | Upgrade
|
| Total Current Liabilities | 20.31 | 25.36 | 11.5 | 3.99 | 3.56 | 2.77 | Upgrade
|
| Long-Term Leases | 0.43 | 0.49 | 0.55 | 0.17 | 0.3 | 0.42 | Upgrade
|
| Total Liabilities | 20.75 | 25.85 | 12.05 | 4.16 | 3.86 | 3.19 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 246.54 | 182.92 | 168.14 | 182.56 | 161.53 | 119.59 | Upgrade
|
| Retained Earnings | -244.99 | -202.76 | -159.99 | -150.9 | -126.78 | -111.68 | Upgrade
|
| Total Common Equity | 1.55 | -19.84 | 8.15 | 31.66 | 34.76 | 7.91 | Upgrade
|
| Shareholders' Equity | 16.55 | -13.78 | 9.54 | 33.05 | 54.79 | 9.06 | Upgrade
|
| Total Liabilities & Equity | 37.29 | 12.08 | 21.59 | 37.2 | 58.66 | 12.25 | Upgrade
|
| Total Debt | 0.51 | 0.55 | 0.6 | 0.3 | 0.42 | 0.53 | Upgrade
|
| Net Cash (Debt) | 33.75 | 9.01 | 19.26 | 35.4 | 56.74 | 10.09 | Upgrade
|
| Net Cash Growth | 83.25% | -53.21% | -45.59% | -37.61% | 462.53% | -23.89% | Upgrade
|
| Net Cash Per Share | 1.13 | 0.74 | 2.73 | 6.38 | 28.64 | 13.14 | Upgrade
|
| Filing Date Shares Outstanding | 40.57 | 32.26 | 9.74 | 6.11 | 5.05 | 0.94 | Upgrade
|
| Total Common Shares Outstanding | 40.57 | 20.74 | 9.39 | 6.11 | 4.54 | 0.94 | Upgrade
|
| Working Capital | 15.58 | -14.91 | 9.03 | 32.58 | 54.38 | 8.62 | Upgrade
|
| Book Value Per Share | 0.04 | -0.96 | 0.87 | 5.18 | 7.65 | 8.43 | Upgrade
|
| Tangible Book Value | 1.55 | -19.84 | 8.15 | 31.66 | 34.76 | 7.91 | Upgrade
|
| Tangible Book Value Per Share | 0.04 | -0.96 | 0.87 | 5.18 | 7.65 | 8.43 | Upgrade
|
| Machinery | - | 1.66 | 0.8 | 0.58 | 0.45 | 0.43 | Upgrade
|
| Leasehold Improvements | - | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.